Respiratory Syncytial Virus (RSV) is a major global cause of childhood morbidity and mortality. Palivizumab, a monoclonal antibody that provides passive immunity against RSV, is currently licensed for prophylactic use in specific “high-risk” populations, including congenital heart disease, bronchopulmonary dysplasia and prematurity. Available research suggests palivizumab use in these high-risk populations can lead to a reduction in RSV-related hospitalization. However, palivizumab has not been demonstrated to reduce mortality, adverse events or length of hospital stay related to RSV. In this article, we review the management of RSV, indications for palivizumab prophylaxis, the safety, cost-effectiveness and efficacy of this preventative medication, and emerging therapeutics that could revolutionize future prevention of this significant pathogen.
Bibliographical noteFunding Information:
HEG previously received honoraria for presenting at an RSV-educational event sponsored by an AstraZeneca Educational grant and for presenting at an RSV-educational event sponsored by AbbVie. MS reports personal fees from Sanofi Pharmaceutical, outside the submitted work. All other authors declare no conflicts of interest in this work.
© 2023 O’Hagan et al. This work is published and licensed by Dove Medical Press Limited.
- future directions
ASJC Scopus subject areas
- Health Policy